MCM
PBYI icon

MAI Capital Management’s Puma Biotechnology PBYI Stock Holding History

MAI Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,558
Closed -$48.3K – 3942
2026
Q1 		$48.3K Buy
7,558
+7,521
+20,327% +$48.5K ﹤0.01% 2253
2025
Q4 		$221 Buy
+37
New +$196 ﹤0.01% 4020

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MAI Capital Management's PBYI Position: Q2 2026 in Review

MAI Capital Management sold out of Puma Biotechnology (PBYI) in Q2 2026, closing a stake of 7,558 shares — an estimated $48.3K sold.

MAI Capital Management first reported a position in PBYI in Q4 2025 and held it in 2 quarters. The position peaked at $48.3K in Q1 2026. 160 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

  • MAI Capital Management reported no remaining Puma Biotechnology position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 7,558 Puma Biotechnology shares in Q2 2026, an estimated $48.3K.
  • MAI Capital Management first reported a position in Puma Biotechnology in Q4 2025 and held it in 2 quarters.
  • MAI Capital Management's Puma Biotechnology position peaked at $48.3K in Q1 2026.
  • 160 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.